Theravance Biopharma (TBPH) Operating Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Operating Expenses data on file, last reported at $27.2 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $27.2 million, down 8.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $108.4 million (down 6.08% YoY), and the FY2025 annual result was $111.1 million, changed 0.24% from the prior year.
• Operating Expenses rose to $27.2 million in Q1 2026 per TBPH's latest filing, from $25.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $51.7 million in Q1 2022 and troughed at $21.6 million in Q3 2022.
• A 5-year average of $29.8 million and a median of $28.0 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses sank 67.68% in 2022, then increased 17.43% in 2024.
• A 5-year view of Operating Expenses shows it stood at $32.1 million in 2022, then retreated by 25.8% to $23.8 million in 2023, then advanced by 17.43% to $28.0 million in 2024, then slipped by 7.42% to $25.9 million in 2025, then gained by 5.03% to $27.2 million in 2026.
• Business Quant data shows TBPH's Operating Expenses at $27.2 million in Q1 2026, $25.9 million in Q4 2025, and $26.4 million in Q3 2025.